MWM
RNA

Moran Wealth Management’s Atrium Therapeutics RNA Stock Holding History

Moran Wealth Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
+33,320
New +$435K 0.01% 428

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Moran Wealth Management's RNA Position: Q2 2026 in Review

Moran Wealth Management opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 33,320 shares worth $448K. The stake represents 0.01% of the portfolio and ranks #428 among its holdings.

34 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Moran Wealth Management held 33,320 shares of Atrium Therapeutics worth $448K as of Q2 2026.
  • Atrium Therapeutics was a new Moran Wealth Management position in Q2 2026.
  • Atrium Therapeutics made up 0.01% of Moran Wealth Management's portfolio in Q2 2026, its #428 holding.
  • 34 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.